Walid Macaron

1.0k total citations
22 papers, 181 citations indexed

About

Walid Macaron is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Walid Macaron has authored 22 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Public Health, Environmental and Occupational Health, 17 papers in Hematology and 15 papers in Genetics. Recurrent topics in Walid Macaron's work include Acute Lymphoblastic Leukemia research (18 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Walid Macaron is often cited by papers focused on Acute Lymphoblastic Leukemia research (18 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Walid Macaron collaborates with scholars based in United States, Lebanon and France. Walid Macaron's co-authors include Nicholas J. Short, Farhad Ravandi, Nitin Jain, Elias Jabbour, Hagop M. Kantarjian, Musa Yılmaz, Tapan M. Kadia, Marina Konopleva, Keyur P. Patel and Rebecca Garris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Oncology.

In The Last Decade

Walid Macaron

20 papers receiving 180 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Walid Macaron United States 7 128 118 91 34 26 22 181
Laura Kingsbury United States 6 161 1.3× 143 1.2× 86 0.9× 30 0.9× 35 1.3× 8 219
Lewis Nasr United States 9 80 0.6× 80 0.7× 54 0.6× 29 0.9× 26 1.0× 27 139
Jordi Ribera Spain 7 105 0.8× 120 1.0× 41 0.5× 22 0.6× 22 0.8× 15 150
Grigory Tsaur Russia 8 113 0.9× 116 1.0× 41 0.5× 23 0.7× 58 2.2× 57 195
Catherine Tuglus United States 8 77 0.6× 119 1.0× 110 1.2× 18 0.5× 15 0.6× 12 193
Jennie B. Feliu United States 6 137 1.1× 92 0.8× 40 0.4× 29 0.9× 107 4.1× 6 219
Nikola Hagedorn Germany 6 158 1.2× 223 1.9× 65 0.7× 23 0.7× 22 0.8× 11 258
Samuel Dara United States 5 255 2.0× 256 2.2× 67 0.7× 75 2.2× 33 1.3× 10 313
Rosane Bittencourt Brazil 10 163 1.3× 63 0.5× 71 0.8× 34 1.0× 102 3.9× 39 238
Rajni Agarwal‐Hashmi United States 5 76 0.6× 44 0.4× 54 0.6× 24 0.7× 16 0.6× 11 155

Countries citing papers authored by Walid Macaron

Since Specialization
Citations

This map shows the geographic impact of Walid Macaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walid Macaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walid Macaron more than expected).

Fields of papers citing papers by Walid Macaron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walid Macaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walid Macaron. The network helps show where Walid Macaron may publish in the future.

Co-authorship network of co-authors of Walid Macaron

This figure shows the co-authorship network connecting the top 25 collaborators of Walid Macaron. A scholar is included among the top collaborators of Walid Macaron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walid Macaron. Walid Macaron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Short, Nicholas J., Elias Jabbour, Walid Macaron, et al.. (2025). Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer Journal. 15(1). 169–169.
2.
3.
4.
Short, Nicholas J., Elias Jabbour, Walid Macaron, et al.. (2023). Ultrasensitive NGS MRD assessment in Ph+  ALL : Prognostic impact and correlation with RT‐PCR for BCR::ABL1. American Journal of Hematology. 98(8). 1196–1203. 37 indexed citations
5.
6.
7.
Zerdan, Maroun Bou, Joseph Kassab, Morgan Bou Zerdan, et al.. (2023). Liquid biopsies and minimal residual disease in lymphoid malignancies. Frontiers in Oncology. 13. 1173701–1173701. 5 indexed citations
8.
Short, Nicholas J., Elias Jabbour, Nitin Jain, et al.. (2023). P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY. HemaSphere. 7(S3). e67564ca–e67564ca. 2 indexed citations
9.
10.
Nasr, Lewis, Nicholas J. Short, Jayastu Senapati, et al.. (2023). Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.. Journal of Clinical Oncology. 41(16_suppl). e19008–e19008. 2 indexed citations
11.
12.
13.
Short, Nicholas J., Elias Jabbour, Nitin Jain, et al.. (2023). A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 41(16_suppl). e19017–e19017. 8 indexed citations
14.
Macaron, Walid, et al.. (2022). Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. Current Problems in Cancer. 46(3). 100859–100859. 9 indexed citations
15.
16.
Jabbour, Elias, Nicholas J. Short, Nitin Jain, et al.. (2022). Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. The Lancet Haematology. 9(12). e878–e885. 43 indexed citations
17.
Macaron, Walid, et al.. (2022). Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & lymphoma. 63(8). 1780–1791. 13 indexed citations
18.
Ravandi, Farhad, Naveen Pemmaraju, Marina Konopleva, et al.. (2022). A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematologica. 145(5). 529–536. 27 indexed citations
19.
Short, Nicholas J., Hagop M. Kantarjian, Marina Konopleva, et al.. (2022). A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).. Journal of Clinical Oncology. 40(16_suppl). 7009–7009. 6 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Kingsbury Breakdown of academic impact, for papers by Lewis Nasr Breakdown of academic impact, for papers by Jordi Ribera Breakdown of academic impact, for papers by Grigory Tsaur Breakdown of academic impact, for papers by Catherine Tuglus Breakdown of academic impact, for papers by Jennie B. Feliu Breakdown of academic impact, for papers by Nikola Hagedorn Breakdown of academic impact, for papers by Samuel Dara Breakdown of academic impact, for papers by Rosane Bittencourt Breakdown of academic impact, for papers by Rajni Agarwal‐Hashmi
Rankless by CCL
2026